Contains Promotional Content - For UK Healthcare Professionals Only
Female clinician smiling

Multiple Myeloma

Multiple myeloma is a blood cancer accounting for 2% of cancers in the United Kingdom1. Despite available treatments, Multiple myeloma remains an incurable malignancy and is associated with significant patient burden, with patients relapsing over time2. As they relapse, patients can become refractory/resistant to treatments3.

Sanofi Genzyme Oncology is committed to the management of patients with multiple myeloma. Sarclisa®▼ (isatuximab) in combination with pomalidomide and dexamethasone (Pd) is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (PI) and have demonstrated disease progression on the last therapy4

Multiple Myeloma Graphic

Information On Sarclisa

The Sarclisa UK website has been developed to provide access to information to support the prescribing and administration of Sarclisa combination therapy, for the multidisciplinary team managing patients with multiple myeloma. 

Please click on the link below to access this promotional website.

Sarclisa Supporting Materials

Materials To Support Treating Patients With Sarclisa

The following materials are available to support you and your patients. Patient materials should only be issued once a decision to prescribe Sarclisa has been made.

References:
1. Cancer Research UK. Myeloma statistics. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-
cancer-type/myeloma (last accessed October 2021). 2. Myeloma UK. What is myeloma? Available at: https://www.myeloma.org.uk/understanding-myeloma/what-is-myeloma (last accessed October 2021). 3. Kurtin SE (2013) Relapsed or Relapsed/Refractory Multiple Myeloma. Advancedpractitioner.com: Vol 4, No. 6, Suppl 1. Available at: https://www.advancedpractitioner.com/media/164110/005.pdf (last accessed October 2021). 4. Sarclisa Summary of Product Characteristics (SmPC). Available at: https://www.medicines.org.uk/emc/product/11535/smpc (last accessed October 2021).

Report an Adverse Event

Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for "MHRA Yellowcard" in the Google Play or Apple App Store. Adverse Events should also be reported to the Sanofi Drug Safety Department on:

 0800 0902 314
 UK-drugsafety@sanofi.com

Report a Product Technical Complaint

In the case of any Product Technical Complaints, please report these by emailing the Sanofi Quality Department at UK-ProductQualityComplaints@sanofi.com